PUBLISHER: The Business Research Company | PRODUCT CODE: 1939331
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939331
The bilirubin blood test is a diagnostic procedure used to measure bilirubin levels in the blood. This test is important for evaluating liver function and diagnosing conditions such as jaundice and liver disease. It is crucial for assessing bilirubin metabolism and identifying liver health issues.
The main types of bilirubin blood tests includes the total serum bilirubin test, the indirect or unconjugated bilirubin test, and the direct or conjugated bilirubin test. The total serum bilirubin test measures the combined amount of unconjugated (indirect) and conjugated (direct) bilirubin in the blood. This test is essential for assessing overall liver health and diagnosing various liver-related conditions. The test is applicable to adults, pediatrics, and infants, and it is used in hospitals, clinics, and other healthcare settings.
Tariffs are affecting the bilirubin blood test market by increasing the costs of diagnostic analyzers, reagent kits, assay consumables, and laboratory instrumentation components that depend on cross-border supply chains, leading to higher procurement and testing costs. The impact is most evident across hospitals and clinical laboratories, especially in regions such as Asia-Pacific and Europe where reagent imports and analyzer components are tariff sensitive. Pediatric, infant, and adult testing segments are experiencing cost pressures and slower equipment upgrade cycles due to tariff-driven price pass-throughs. At the same time, tariffs are encouraging localized reagent manufacturing, regional analyzer assembly, and domestic supply chain development, which may strengthen long-term production resilience and market stability.
The bilirubin blood test market research report is one of a series of new reports from The Business Research Company that provides bilirubin blood test market statistics, including bilirubin blood test industry global market size, regional shares, competitors with a bilirubin blood test market share, detailed bilirubin blood test market segments, market trends and opportunities, and any further data you may need to thrive in the bilirubin blood test industry. This bilirubin blood test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bilirubin blood test market size has grown strongly in recent years. It will grow from $1.46 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rise in neonatal jaundice screening programs, increasing hospital-based liver function testing, growth in diagnostic awareness of liver disorders, adoption of serum bilirubin testing in routine clinical practice, expansion of pediatric and infant diagnostic services.
The bilirubin blood test market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing burden of chronic liver disease and hepatitis, rising demand for early liver health assessment, increasing utilization of bilirubin testing in primary care settings, higher testing rates in aging and at-risk patient populations, expansion of point-of-care and specialty liver diagnostics. Major trends in the forecast period include increasing use of bilirubin testing for liver function assessment, growing adoption of bilirubin tests in neonatal jaundice screening, rising testing demand in hematology and preliver disorder evaluation, expansion of bilirubin monitoring across hospital and clinical settings, focus on early detection and routine screening for liver health.
The increasing incidence of liver diseases is expected to drive the growth of the bilirubin blood test market in the coming years. Liver diseases encompass a variety of conditions that hinder normal liver function and may arise from causes such as infections, excessive alcohol intake, or metabolic disorders. The rise in liver disease cases is largely linked to growing obesity rates, high alcohol consumption, viral infections, and unhealthy lifestyle habits, all of which contribute to liver damage and dysfunction. Liver disease can markedly affect bilirubin levels in the body, and bilirubin blood tests are used to diagnose and monitor liver function, offering essential information about patient health while supporting healthcare professionals in the effective management and treatment of liver-related conditions. For instance, in April 2023, according to GOV.UK, a UK-based department for science, innovation, and technology, hospital admission rates for liver disease rose from 150.6 (148.2-152.9) to 155.2 (152.9-157.5) per 100,000 population between the financial years ending 2022 and 2023, highlighting a sustained upward trend in liver disease-related hospitalizations. Therefore, the growing incidence of liver diseases is driving the growth of the bilirubin blood test market.
Leading companies in the bilirubin blood test market are increasingly forming strategic partnerships to broaden their reach and improve their offerings. A strategic partnership involves a collaborative relationship between organizations that combines resources and expertise to achieve mutual goals. For example, in December 2023, Calmark Sweden AB, an Israel-based medical diagnostic biotechnology firm, entered into an exclusive distributor agreement with Techno Orbits in Saudi Arabia for its bilirubin test for newborns. Techno Orbits will manage the distribution and sales of Calmark's product, utilizing its established network and connections, including with the Ministry of Health. This partnership aims to facilitate the introduction of Calmark's bilirubin test into the Saudi market, with regulatory registration expected to take between 3 to 6 months.
In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a China-based medical technology provider, acquired a 75% stake in DiaSys Diagnostic Systems GmbH for an undisclosed sum. This acquisition is designed to bolster Mindray's competitive position in the in vitro diagnostic (IVD) sector by leveraging DiaSys's established supply chains and expertise in clinical chemistry. The acquisition is expected to enhance Mindray's capabilities in serving medium- to large-volume customers and improve service delivery. DiaSys Diagnostic Systems GmbH, based in Germany, specializes in diagnostic systems, including bilirubin blood tests for liver diseases.
Major companies operating in the bilirubin blood test market are Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Danaher Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, Mindray Medical International Limited, Randox Laboratories Ltd, bioMerieux SA, DiaSorin S.p.A, Horiba Ltd, ELITech Group SAS, Erba Mannheim, Hitachi High-Technologies, DIRUI Industrial Co Ltd, Agappe Diagnostics, Awareness Technology Inc, Sekisui Diagnostics
North America was the largest region in the bilirubin blood test market in 2025. The regions covered in the bilirubin blood test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the bilirubin blood test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The bilirubin blood test market consists of sales of products such as diagnostic devices for measuring bilirubin levels, including test kits, blood analyzers, and automated testing systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bilirubin Blood Test Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses bilirubin blood test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bilirubin blood test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bilirubin blood test market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.